Vedanta Biosciences wins FDA fast track designation for Clostridioides difficile treatment

Published on 12 May 2023

Vedanta Biosciences has obtained fast track designation from the US Food and Drug Administration (FDA) for its live biotherapeutic VE303, a preventative treatment for recurrent Clostridioides difficile infection (CDI).

Continue reading on website
Other news

Lessons Learned from COVID-19 Are Informing Preparation for Future Public Health Emergencies

12 May 2023
While the HHS public health emergency is ending, COVID-19 remains a high priority and the U.S. Food and Drug Administration will remain engaged with numerous activities to protect and promote public health.

UCB partners with Ariceum for treatment of immune-related diseases and cancer

12 May 2023
UCB and Ariceum have announced a strategic research collaboration to identify and develop systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases.